This is a summary of the American Academy of Neurology (AAN) guideline regarding management and care of the patient with amyotrophic lateral sclerosis (ALS). Recommendations are presented for drug, nutritional, and respiratory therapies.

Please refer to the full guideline at www.aan.com for more information, including the AAN’s definitions of the levels of recommendations and classifications of evidence.

### DRUG THERAPIES

<table>
<thead>
<tr>
<th>Question</th>
<th>Evidence Level</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is the effect of riluzole on slowing the disease process or prolonging survival in ALS?</td>
<td>Strong evidence</td>
<td>Riluzole should be offered to slow disease progression in patients with ALS (Level A).</td>
</tr>
<tr>
<td>Does lithium carbonate prolong survival or slow disease progression in ALS?</td>
<td>Insufficient evidence</td>
<td>There are insufficient data at this time to support or refute treatment with lithium carbonate in patients with ALS (Level U).</td>
</tr>
</tbody>
</table>

### NUTRITIONAL THERAPIES

<table>
<thead>
<tr>
<th>Question</th>
<th>Evidence Level</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is the effect of enteral nutrition administered via percutaneous endoscopic gastrostomy (PEG) on weight stability?</td>
<td>Good evidence</td>
<td>In patients with ALS with impaired oral food intake, enteral nutrition via PEG should be considered to stabilize body weight (Level B).</td>
</tr>
<tr>
<td>When is PEG indicated in ALS?</td>
<td>Insufficient evidence</td>
<td>There are insufficient data to support or refute specific timing of PEG insertion in patients with ALS (Level U).</td>
</tr>
<tr>
<td>What is the efficacy of nutritional support via PEG in prolonging survival?</td>
<td>Good evidence</td>
<td>PEG should be considered for prolonging survival in patients with ALS (Level B).</td>
</tr>
<tr>
<td>What is the effect of enteral nutrition delivered via PEG on quality of life (QOL)?</td>
<td>Insufficient evidence</td>
<td>There are insufficient data to support or refute PEG for improving QOL in patients with ALS (Level U).</td>
</tr>
<tr>
<td>What is the efficacy of vitamin and nutritional supplements on prolonging survival or QOL?</td>
<td>Strong evidence</td>
<td>Creatine, in doses of 5 to 10 g daily, should not be given as treatment for ALS because it is not effective in slowing disease progression (Level A).</td>
</tr>
<tr>
<td>Good evidence</td>
<td>High-dose vitamin E should not be considered as treatment for ALS (Level B).</td>
<td></td>
</tr>
<tr>
<td>Insufficient evidence</td>
<td>The equivocal evidence regarding low-dose vitamin E permits no recommendation (Level U).</td>
<td></td>
</tr>
</tbody>
</table>

### RESPIRATORY THERAPIES

<table>
<thead>
<tr>
<th>Question</th>
<th>Evidence Level</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>What are the optimal pulmonary tests to detect respiratory insufficiency?</td>
<td>Weak evidence</td>
<td>Nocturnal oximetry may be considered to detect hypoventilation (regardless of the forced vital capacity [FVC]) (Level C).</td>
</tr>
<tr>
<td>Supine FVC and maximal inspiratory pressure (MIP) may be considered useful in routine respiratory monitoring, in addition to the erect FVC (Level C).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sniff nasal pressure (SNP) may be considered to detect hypercapnia and nocturnal hypoxemia (Level C).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does noninvasive ventilation (NIV) improve respiratory function or increase survival?</td>
<td>Good evidence</td>
<td>NIV should be considered to treat respiratory insufficiency in ALS, both to lengthen survival and to slow the rate of FVC decline (Level B).</td>
</tr>
<tr>
<td>How do invasive ventilation and NIV affect QOL?</td>
<td>Weak evidence</td>
<td>NIV may be considered to enhance QOL in patients with ALS who have respiratory insufficiency (Level C).</td>
</tr>
<tr>
<td>Tracheostomy invasive ventilation (TIV) may be considered to preserve QOL in patients with ALS who want long-term ventilatory support. (Level C).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>What factors influence acceptance of invasive ventilation and NIV?</td>
<td>Weak evidence</td>
<td>NIV may be considered at the earliest sign of nocturnal hypoventilation or respiratory insufficiency in order to improve compliance with NIV in patients with ALS (Level C).</td>
</tr>
<tr>
<td>What is the efficacy of targeted respiratory interventions for clearing secretions?</td>
<td>Weak evidence</td>
<td>Mechanical insufflation/exsufflation (MIE) may be considered to clear secretions in patients with ALS who have reduced peak cough flow, particularly during an acute chest infection (Level C).</td>
</tr>
</tbody>
</table>
Insufficient evidence

There are insufficient data to support or refute high-frequency chest wall oscillation (HFCWO) for clearing airway secretions in patients with ALS (Level U).

**Clinical context**

Medications with mucolytics, a B-receptor antagonist, nebulized saline, or an anticholinergic bronchodilator are widely used; however, no controlled studies exist in ALS.

**CLINICAL CONTEXT**

The ALS patient CARE database was developed with the hope of standardizing new and effective therapies for patients with ALS and tracking outcomes to raise the standard of care. Data obtained from the ALS CARE program have shown that the underutilization of many therapies has persisted in the years since the previous practice parameter, though there have been gains. These findings suggest that an evidence-based practice parameter may over time become more widely accepted and change practice. However, the persistent underutilization of therapies that improve survival and QOL poses a challenge for ALS clinicians to continue to raise the standard of care for patients with ALS.

*Clinical context slightly abridged. See the published guideline for the complete text.

The following figures present approaches to nutritional and respiratory management in patients with ALS.

**Figure 1. Nutrition management algorithm**

- **Monitor body weight**
- **Dysphagia assessment instrument**
- **Monitor Respiratory status (FVC, MIP, etc.)**

**Diagnosis ALS**

- Clinic visits every 3 months
- Early dysphagia detected
- Nutritional education including PEG

**Symptom progression** or **continuing weight loss**

**Discuss PEG to stabilize weight and possibly prolong survival**

- FVC > 50%
- FVC 30-50%
- FVC < 30%

**Low risk for PEG**

**PEG accepted**

- Anesthesia evaluation
- Experienced gastroenterologist
- Respiratory support during PEG if needed

**PEG declined**

- Oral intake as tolerated
- Enteral nutrition via PEG as needed

**Oral intake as tolerated**

**Palliative IV hydration, Palliative NG feeding**

1 *e.g., bulbar questions in the Amyotrophic Lateral Sclerosis Functional Rating Scale, or other instrument.

2 *Percutaneous endoscopic gastrostomy: rule out contraindications.

3 Prolonged meal time; ending meal prematurely because of fatigue; accelerated weight loss due to poor caloric intake; family concern about feeding difficulties.

**Figure 2. Respiratory management algorithm**

- **Diagnosis ALS**

**Orthopnea or SNP < 40 cm or MIP < -60 cm or Abnl nocturnal oximetry or FVC < 50%**

**Consider NIV**

- NIV tolerated?

Yes

- Further education regarding documented benefits; Evaluate reasons for noncompliance
- Ongoing evaluations and adjustment of pressures

No

- Reintroduce NIV

Not successful

- Hospice referral

**Unable to maintain pO2 > 90%, pCO2 < 50mmHg or unable to manage secretions**

1 Symptoms suggestive of nocturnal hypoventilation:

- Frequent arousals
- Morning headaches
- Excessive daytime sleepiness
- Vivid dreams

2 If NIV is not tolerated or accepted in the setting of advancing respiratory compromise, consider invasive ventilation or referral to hospice.

**Text in italic = consensus-based**

**Text in bold = evidence-based**

This is an educational service of the American Academy of Neurology. It is designed to provide members with evidence-based guideline recommendations to assist the decision making in patient care. It is based on an assessment of current scientific and clinical information and is not intended to exclude any reasonable alternative methodologies. The AAN recognizes that specific patient care decisions are the prerogative of the patient and the physician caring for the patient, and are based on the circumstances involved. Physicians are encouraged to carefully review the full AAN guidelines so they understand all recommendations associated with care of these patients.

©2009 American Academy of Neurology

Copies of this summary and additional companion tools are available at www.aan.com or through AAN Member Services at (800) 879-1960.